Significance of tumor marker determinations in the primary therapy of ovarian cancer

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 2949-2951

  Meier, Werner ^a   Baumgartner, Ludwig ^a   Stieber, Petra ^a   Hasholzner, Ute ^a   Fateh Moghadam, Ahmad ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CA125; Ovarian cancer; Prognosis; Tumor marker

Indexed keywords

CA 125 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; CYSTADENOCARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MUCINOUS CARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030750982     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331, 1981
2. Meier W, Stieber P, Baumgartner L, Hasholzner U, Fateh-Moghadam A: 10 years experience with the tumor marker CA125 in ovarian cancer. In: Current tumor diagnosis: Applications, clinical relevance, research-trends (Klapdor R, edt). Zuckschwerdt, München, 1994, 811
3. Niloff JM, Knapp RC, Lavin PT, et al: The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer Am J Obstet Gynecol 155: 56, 1986
4. Meier W, Stieber P, Eiermann W, Schneider A, Fateh-Moghadam A, Hepp H: Serum levels of CA125 and histological findings at second-look laparotomy in ovarian carcinoma. Gynecol Oncol 35: 44, 1989
5. Tholander B, Taule A, Lindgren A, et al: Pretreatment serum levels of CA125, carcinoembryonic antigen, tissue polypeptide antigen and placental alkaline phosphatase in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: Relevance for differential diagnosis. Gynecol Oncol 39: 16, 1990
6. Davidson NG, Khanna S, Kirwan PH, Bircumshaw D: Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin Oncol R Coll Radiol 3: 32, 1991
7. Kreienberg R: Immundiagnostik und ihre Relevanz bei Tumorerkrankungen, Immuntherapie bei Tumorerkrankungen. Gynäkologe 23: 122, 1989
8. van der Burg MEL, Lammers FB, Verweij J: Ovarian cancer: The prognostic value of the serum half life of CA125 during induction chemotherapy. Gynecol Oncol 30: 307, 1988
9. Meier W, Stieber P, Fateh-Moghadam A, Eiermann W, Hepp H: Prognostische Bedeutung der CA125-Halbwertszeit für den weiteren Krankheitsverlauf beim Ovarialkarzinom. Geburtsh u Frauenheilk 53: 30, 1992
10. McGuire WP, Rowinsly EK, Rosenshein NB, et al: Taxol: An unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273, 1989